Aemetis, Inc. (AMTX) At $0.66 Forms Bottom; Trillium Therapeutics Inc. (TRIL) Had 3 Analysts Last Week

Aemetis, Inc. (AMTX) formed multiple bottom with $0.63 target or 4.00% below today’s $0.66 share price. Aemetis, Inc. (AMTX) has $13.08 million valuation. The stock decreased 5.67% or $0.04 during the last trading session, reaching $0.66. About 1,299 shares traded. Aemetis, Inc. (NASDAQ:AMTX) has declined 50.79% since February 4, 2017 and is downtrending. It has underperformed by 67.49% the S&P500.

Among 3 analysts covering Trillium Therapeutics (NASDAQ:TRIL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Trillium Therapeutics had 5 analyst reports since August 26, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of TRIL in report on Wednesday, July 5 with “Buy” rating. The stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) earned “Buy” rating by Ladenburg on Thursday, June 8. The firm has “Buy” rating given on Thursday, December 14 by H.C. Wainwright. The rating was upgraded by Zacks on Wednesday, August 26 to “Hold”. See Trillium Therapeutics Inc. (NASDAQ:TRIL) latest ratings:

14/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company has market cap of $96.62 million. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. It currently has negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

The stock decreased 4.43% or $0.35 during the last trading session, reaching $7.55. About 142,112 shares traded. Trillium Therapeutics Inc. (NASDAQ:TRIL) has declined 39.86% since February 4, 2017 and is downtrending. It has underperformed by 56.56% the S&P500.